e-Newsletter October 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Search
Search results
Help to shape our future
Would you like to help shape Retina UK’s future? Do you want to ensure decision-makers understand the impact of inherited sight loss? If so we’d love to hear from you.
ReNeuron trial FAQs
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
ProQR announces agreement with Laboratoires Théa for inherited retinal disease programmes
Biotechnology company ProQR has announced that two of its RNA therapy development programmes for inherited sight loss are being acquired by Laboratoires Théa, a company specialising in eye care products.
New Young Persons Project from Retina UK
We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.
Podcast: Sight Loss Survey 2025
Join Lauren as she chats with Paula McGrath, Deputy CEO of Retina UK, about the 2025 Sight Loss Survey
Webinar: Genetic Testing: what can I expect?
Webinar: Genetic Testing: what can I expect?
What’s in store: a sneak peek at the Retina UK conferences
The latest podcast from Retina UK.
Clinical Trial Opportunity for Adults with Stargardt Disease
The Retina Clinic London have asked us to share an opportunity to participate in a clinical trial.
Does gene therapy always have to be gene-specific?
Early 2020 marked an important milestone for the Retina UK community, when the first person with an inherited retinal condition received NHS treatment to potentially slow or even stop the progression of their sight loss.